GSK Sees Light At End Of Shingrix Tunnel As COVID-19 Eases
Company Records Steep Sales Decline For Shingles Vaccine in Q1
Executive Summary
A CDC recommendation slowed non-pandemic vaccinations, but Shingrix shots will likely increase as more eligible consumers are fully vaccinated against SARS-CoV-2.
You may also be interested in...
GSK’s Shingrix On Recovery Track In Q3 After Pandemic Slump
The shingles vaccine’s move to health care practices, as well as inventory moves, contributed to its 41% sales growth during the quarter after a difficult year due to COVID-19.
Pharma Is Poised For A COVID-19 Recovery; Will Q2 Deliver?
The second quarter could mark a financial turning point for big pharma as demand rebounds from the pandemic, but variability remains across portfolios and therapeutic areas.
Walmsley Under Pressure Over GSK’s Strategy
GSK’s share price is down by 15% since Walmsley took over as CEO, but major investors are said to be resisting calls for a radical re-think in its strategy.